Tedor Pharma has recently made changes to its management team. Doug Drysdale was appointed president and chief executive officer in February 2018. Mr. Drysdale joined the company’s board in November 2017 and brings 28 years of pharmaceutical experience, most recently as chairman and chief executive officer of Pernix Therapeutics, and founding chief executive officer of Alvogen.
 
Also, Terry Novak joined the company in February 2018 as chief operating officer. Mr. Novak has more than 35 years of business development and operational experience in the pharmaceutical and CDMO industries having served as president of DSM Pharmaceuticals, Patheon and Norwich Pharmaceuticals. Most recently, he served as chief operating officer of Pernix Therapeutics.
 
Additionally, Steve Tannenbaum continues in his role as Tedor’s chief financial officer. He has extensive pharmaceutical experience having served as chief financial officer of Copley Pharmaceuticals and Precision Dermatology.
 
Effective immediately, Mike Young, vice president of operations and Mike Maciocio, formerly vice president of facilities, will report to Mr. Novak. Mr. Maciocio will be taking on a new role as vice president, Operations Planning, responsible for the development of cross-functional workflow processes to ensure that project milestones are achieved and delivered on time. 
 
Melissa Nobrega, vice president of Human Resources, will now report directly to Mr. Drysdale as well as Dennis Hall, vice president of Quality.
 
“In these roles, Mike Maciocio, Mike Young and Dennis Hall will work together to drive our continuous improvement efforts and the customer experience. The work that we do here at Tedor is of great value to our customers and the patients they serve. It is our goal to ensure that we do the best job we can do for every customer every single day,” said Mr. Novak.